Company intelligence / Profile preview

TxCell

Ownership: Private
Employees: ~44
Development stage: Phase 2

Overview

TxCell completed enrollment of a Phase I/II study in refractory Crohn’s disease with positive results. Ovasave advanced to Phase IIb. Col-Treg received EU orphan drug designation for non-infectious uveitis but had not yet entered the clinic by acquisition. No commercial products at time of acquisition.

Therapeutic areas: GastroenterologyImmunologyNeurology
Modalities: Cell therapy (regulatory T cells/Tregs, CAR-Tregs)Personalized T cell immunotherapies
Industry: Biotech

Drug pipeline

2 assets

Ovasave

Phase 2

Indications: Crohn's Disease

1 more asset in the full pipeline.

Request access →

Partnerships

CMO partners for manufacturing transferInserm as original spin-off institutionno major pharma partnerships disclosed.

Beyond the preview

Go deeper on TxCell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TxCell.

Explore the full profile